Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
1. A method for reducing the incidence of a bleeding episode in a human subject in need thereof comprising administering to the subject multiple doses of a long-acting Factor VIII (FVIII) polypeptide at a dosing interval of 3 to 7 days between two doses of the long-acting FVIII polypeptide,
wherein the therapeutic dose is about 25 IU/kg to about 65 IU/kg,
wherein the long-acting FVIII polypeptide is an FVIIIFc monomer dimer hybrid-comprising a FVIII portion and two Fc portions, wherein one of the Fc portions is fused to the C-terminus of the light chain of the FVIII portion.
2. The method of claim 1 , wherein the subject has hemophilia A.
3. The method of claim 1 , wherein the reducing the incidence of a bleeding episode prevents or treats the bleeding episode.
4. The method of claim 1 , wherein the administration is for prophylaxis of the bleeding episode or for tailored prophylaxis.
5. The method of claim 1 , wherein a trough level of plasma Factor VIII:C in the subject after the administration is maintained above 1 IU/dl.
6. The method of claim 1 , wherein the therapeutic dose is 25 IU/kg, 30 IU/kg, 35 IU/kg, 40 IU/kg, 45 IU/kg, 50 IU/kg, 55 IU/kg, 60 IU/kg, 65 UI/kg.
7. The method of claim 1 , wherein the dosing interval is three days, four days, five days, six days, or seven days.
8. The method of claim 1 , wherein the dosing interval is about twice a week.
9. The method of claim 1 , wherein the therapeutic dose is about 65 IU/kg.
10. The method of claim 9 , wherein the dosing interval is about four days.
11. The method of claim 1 , comprising administering to the subject twice weekly, a first therapeutic dose of about 25 IU/kg to about 65 IU/kg of the long-acting FVIII polypeptide and a second therapeutic dose of about 25 IU/kg to about 65 IU/kg of the long-acting FVIII polypeptide.
12. The method of claim 11 , wherein the dosing interval between the first dose and the second dose is 72 hours to five days.
13. The method of claim 1 , wherein the administration resolves greater than 5-20%, greater than 5-15%, greater than 5-10%, greater than 10-20%, or greater than 10-15% of bleeding episode.
14. The method of claim 1 , wherein the long-acting FVIII polypeptide is pegylated Factor VIII.
15. The method of claim 1 , wherein the FVIII portion comprises LH-length factor VIII, mature factor VIII, or factor VIII with a full or partial deletion of the B domain.
16. The method of claim 1 , which further exhibits one or more characteristics selected from:
(i) wherein a mean clearance (CL) (activity) in the subject is about 2.33±1.08 mL/hour/kg or less;
(ii) wherein a mean residence time (MRT) (activity) in the subject is about 1.5 fold longer than the MRT of a polypeptide consisting of said FVIII portion;
(iii) wherein a T 1/2 (activity) in the subject is about 1.5 fold longer than the mean T 1/2 (activity) of a polypeptide consisting of said FVIII portion;
(iv) wherein a mean incremental recovery (K value) in the subject is about 90% of the incremental recovery of a polypeptide consisting of said FVIII portion;
(v) wherein a mean Vss (activity) in the subject is about 37.7 to 79.4 mL/kg;
(vi) wherein a mean AUC/dose (activity) in the subject is about 19.2*h/dL per IU/kg to 81.7 IU*h/dL per IU/kg; and
(vii) a combination thereof.
17. The method of claim 1 , wherein the therapeutic dose is about 50 IU/kg or about 65 IU/kg.
18. The method of claim 11 , wherein the first dose is about 50 IU/kg and the second dose is about 50 IU/kg.
19. The method of claim 18 , wherein the second dose is administered three days or four days after the first dose.
20. The method of claim 11 , wherein the first dose is about 65 IU/kg and the second dose is about 65 IU/kg.
21. The method of claim 20 , wherein the second dose is administered five days or one week after administration of the first dose.
22. The method of claim 19 , wherein a trough level of plasma Factor VIII:C in the subject after the administration is maintained above 1 IU/dl.
23. The method of claim 21 , wherein a trough level of plasma Factor VIII:C in the subject after the administration is maintained above 1 IU/dl.
24. A method for prophylactic treatment of a spontaneous bleeding episode in a human subject comprising administering to the subject multiple doses of a long-acting FVIII polypeptide at a dosing interval of about 3 to 7 days between two doses of the long-acting FVIII polypeptide,
wherein the therapeutic dose is about 25 IU/kg to 65 IU/kg, and
wherein the long-acting FVIII polypeptide is a FVIIIFc monomer dimer hybrid-comprising a FVIII portion and two Fc portions, wherein one of the Fc portions is fused to the C-terminus of the light chain of the FVIII portion, and
wherein the spontaneous bleeding episode is prophylactically treated.
25. The method of claim 24 , wherein the FVIII portion comprises full-length factor VIII, mature factor VIII, or factor VIII with a full or partial deletion of the B domain.
26. A method for reducing the incidence of a bleeding episode in a human subject comprising administering to the subject multiple doses of a chimeric polypeptide comprising a FVIIIFc monomer dimer hybrid at a dosing interval of about 3 to 7 days between two doses of the chimeric polypeptide,
wherein the therapeutic dose is about 25 IU/Kg to about 65 IU/kg, and
wherein the FVIIIFc monomer dimer hybrid comprises a FVIII portion and two Fc portions, wherein one of the two Fc portions is fused to the C-terminus of the light chain of the FVIII portion, and
wherein an AUC/dose in the subject is about 19.2-81.7_IU*h/kL per IU/kg, a clearance (CL) (activity) in the subject is about 1.22-5.19 mL/hour/kg, or both.
27. The method of claim 1 , wherein the FVIII portion comprises an amino acid sequence at least 95% identical to amino acids 1 to 1438 of SEQ ID NO: 2.
28. The method of claim 1 , wherein the FVIII portion comprises amino acids 1 to 1438 of SEQ ID NO: 2.
29. The method of claim 1 , wherein the long-acting FVIII polypeptide comprises an amino acid sequence at least 95% identical to amino acids 1 to 1665 of SEQ ID NO: 2.
30. The method of claim 1 , wherein the long-acting FVIII polypeptide comprises amino acids 1 to 1665 of SEQ ID NO: 2.
31. The method of claim 24 , wherein the FVIIIFc monomer dimer hybrid comprises amino acids 1 to 1665 of SEQ ID NO: 2 and amino acids 1 to 227 of SEQ ID NO: 4.